Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition

被引：27
|
作者：
Hude, Ida [1 ,2 ]
Sasse, Stephanie [1 ]
Broeckelmann, Paul J. [1 ]
von Tresckow, Bastian [1 ]
Momotow, Jesko [1 ]
Engert, Andreas [1 ]
Borchmann, Sven [1 ]
机构：
[1] Univ Hosp Cologne, GHSG, Dept Internal Med 1, Cologne, Germany
[2] Univ Hosp Ctr Zagreb, Div Haematol, Dept Internal Med, Zagreb, Croatia
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷 / 06期
关键词：
Hodgkin lymphoma; immune checkpoint inhibition; biomarkers; eosinophils; immunotherapy; BRENTUXIMAB VEDOTIN; NIVOLUMAB; BLOCKADE; FAILURE;
D O I：
10.1111/bjh.14705
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：837 / 840
页数：4
相关论文
共 50 条
  • [41] Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials: LYMPHOMA
    Broeckelmann, P. J.
    Mueller, H.
    Fuchs, M.
    Gillessen, S.
    Eichenauer, D.
    Borchmann, S.
    Robertz, A. S.
    Behringer, K.
    Welters, J.
    Ferdinandus, J.
    Boell, B.
    Tharmaseelan, H.
    Yang, X.
    Kobe, C.
    Eich, H. -t.
    Baues, C.
    Klapper, W.
    Borchmann, P.
    von Tresckow, B.
    LEUKEMIA, 2025, : 988 - 990
  • [42] Dominant negative PD1 armored CAR-T cells induce remission in relapsed or refractory non-Hodgkin lymphoma (NHL) patients
    Yuan, Yan
    Huang, Liansheng
    Su, Yang
    Pu, Chengfei
    Ding, Tianling
    Xiao, Xibin
    Jin, Lina
    Cao, Zhiyuan
    Wu, Ting
    Chen, Tong
    Ding, Luying
    Zhang, Xiaohong
    Lan, Haifeng
    Wu, Zhao
    Xiao, Lei
    CANCER RESEARCH, 2020, 80 (16)
  • [43] Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium
    Iskierka-Jazdzewska, Elzbieta
    Canzian, Federico
    Stepien, Anna
    Martino, Alessandro
    Campa, Daniele
    Stein, Angelica
    Krawczyk-Kulis, Malgorzata
    Rybicka-Ramos, Malwina
    Kyrcz-Krzemien, Slawomira
    Butrym, Aleksandra
    Mazur, Grzegorz
    Jurczyszyn, Artur
    Zawirska, Daria
    Grzasko, Norbert
    Tomczak, Waldemar
    Subocz, Edyta
    Watek, Marzena
    Pasiarski, Marcin
    Rymko, Marcin
    Calbecka, Malgorzata
    Druzd-Sitek, Agnieszka
    Walewski, Jan
    Kruszewski, Marcin
    Razny, Malgorzata
    Zaucha, Jan Maciej
    Dudzinski, Marek
    Gaj, Pawel
    Robak, Tadeusz
    Warzocha, Krzysztof
    Jamroziak, Krzysztof
    LEUKEMIA & LYMPHOMA, 2020, 61 (03) : 699 - 706
  • [44] Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma
    Yan, Xiaoyu
    Xu, Xu Steven
    Weisel, Katja C.
    Mateos, Maria-Victoria
    Sonneveld, Pieter
    Dimopoulos, Meletios A.
    Usmani, Saad Zafar
    Bahlis, Nizar J.
    Puchalski, Thomas
    Ukropec, Jon
    Bellew, Kevin
    Ming, Qi
    Sun, Steven
    Zhou, Honghui
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (06): : 1345 - 1354
  • [45] Outcomes Following Combined Radiotherapy with Brentuximab Vedotin or PD-1 Inhibitors in Relapsed/refractory Classical Hodgkin Lymphoma
    Plastaras, John
    Maxwell, Russell
    Man-Junath, Shwetha
    Twerski, Meshulam
    Carpenter, Maribel
    LaRiviere, Michael
    Paydar, Ima
    Chong, Elise
    Landsburg, Daniel
    Svoboda, Jakub
    Nasta, Sunita
    Schuster, Stephen
    Maity, Amit
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2022, 45 (09): : S14 - S14
  • [46] Response, Progression-Free Survival, and Overall Survival of patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities
    Woyach, Jennifer A.
    Ruppert, Amy S.
    Blum, Kristie A.
    Jones, Jeffrey Alan
    Flynn, Joseph M.
    Johnson, Amy J.
    Grever, Michael R.
    Byrd, John C.
    Heerema, Nyla A.
    BLOOD, 2010, 116 (21) : 1019 - 1020
  • [47] Initial Salvage Approaches for Relapsed/Refractory Mantle Cell Lymphoma Have Comparable Response Rates, Progression-Free and Overall Survival
    Caulfield, Sarah
    Schlafer, Danielle
    Switchenko, Jeffrey M.
    Greenwell, Irl Brian
    Staton, Ashley D.
    Blum, Kristie A.
    Grover, Natalie
    Park, Steven I.
    Danilov, Alexey
    Epperla, Narendranath
    Fenske, Timothy S.
    Hamadani, Mehdi
    Gordon, Max J.
    Mathews, Stephanie
    Valla, Kelly
    Flowers, Christopher
    Cohen, Jonathon B.
    BLOOD, 2017, 130
  • [48] Absolute lymphocyte count and CD4 count predict a superior progression-free survival in non-Hodgkin lymphoma patients treated with rituximab and interleukin-12.
    Joao, C
    Porrata, LF
    Witzig, T
    Kurtin, P
    Micallef, L
    Markovic, SN
    Erlichman, C
    Novak, A
    Ansell, SM
    BLOOD, 2005, 106 (11) : 430A - 431A
  • [49] ASSOCIATION BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH RELAPSED/REFRACTORY (RR) MULTIPLE MYELOMA (MM)
    Mastikhina, L.
    Cope, S.
    Marshall, T.
    Maciel, D.
    Mojebi, A.
    Karampampa, K.
    Dhanda, D.
    VALUE IN HEALTH, 2023, 26 (12) : S30 - S31
  • [50] Tumor-Associated Macrophages Do Not Predict Survival in Relapsed/refractory Hodgkin Lymphoma Treated with Autologous Stem Cell Transplantation
    Siaghani, Parwiz
    Song, Joo
    Chen, Yuan Yuan
    Weisenburger, Dennis D.
    Kim, Young
    MODERN PATHOLOGY, 2017, 30 : 378A - 378A
12345